193 related articles for article (PubMed ID: 15940287)
21. Locally advanced prostate cancer treated with radiotherapy and androgen deprivation.
Kirby R
Nat Clin Pract Urol; 2005 Jun; 2(6):304-8. PubMed ID: 16474813
[TBL] [Abstract][Full Text] [Related]
22. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
23. Metastatic prostate cancer presenting as an asymptomatic neck mass.
Carleton J; van der Riet P; Dahm P
Prostate Cancer Prostatic Dis; 2005; 8(3):293-5; discussion 295. PubMed ID: 15897914
[TBL] [Abstract][Full Text] [Related]
24. [A case of brain metastasis associated with prostate cancer].
Soga N; Sugimura Y
Hinyokika Kiyo; 2004 Jan; 50(1):37-40. PubMed ID: 15032014
[TBL] [Abstract][Full Text] [Related]
25. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
26. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
27. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer.
Loeb S; Smith ND; Roehl KA; Catalona WJ
Urology; 2007 Jun; 69(6):1170-5. PubMed ID: 17572209
[TBL] [Abstract][Full Text] [Related]
28. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
Sandler HM; Eisenberger MA
J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
30. Prostate adenocarcinoma with orbital metastasis in an HIV+ man.
Heintz J; Kahn B; Kramer A
Can J Urol; 2011 Apr; 18(2):5660-2. PubMed ID: 21504657
[TBL] [Abstract][Full Text] [Related]
31. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
32. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
33. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg.
Scattoni V; Montironi R; Mazzucchelli R; Freschi M; Nava L; Losa A; Terrone C; Scarpa RM; Montorsi F; Pappagallo G; Rigatti P
BJU Int; 2006 Jul; 98(1):54-8. PubMed ID: 16831143
[TBL] [Abstract][Full Text] [Related]
34. Proptosis--an uncommon presentation of orbital metastases secondary to prostate cancer.
Vissamsetti B; McArdle PA; Adams CJ; Hotiana Z; Morton AL; Alexander RJ
Urol Int; 2007; 79(4):374-5; discussion 375. PubMed ID: 18025861
[TBL] [Abstract][Full Text] [Related]
35. Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512-8.
Tubaro A; De Nunzio C
Eur Urol; 2004 May; 45(5):674; author reply 674-5. PubMed ID: 15082213
[No Abstract] [Full Text] [Related]
36. Metastatic prostate cancer masquerading clinically and radiologically as a primary caecal carcinoma.
Kabeer MA; Lloyd-Davies E; Maskell G; Hohle R; Mathew J
World J Surg Oncol; 2007 Jan; 5():2. PubMed ID: 17207288
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
38. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
39. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
40. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
